NUP210

Nuclear pore membrane glycoprotein 210 · Q8TEM1 · NUP210 on Sugi Atlas →

0 patent compounds predicted against NUP210, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NUP210 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma PHASE2COMPLETED
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas PHASE1COMPLETED
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) PHASE1WITHDRAWN
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C nanRECRUITING
Clinical and Genetic Examinations of Dilated Cardiomyopathy nanCOMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Cluster Randomized Controlled Screening Trial for NPC nanUNKNOWN
Diagnostic Value of MicroRNA 210 In Preeclampsia nanUNKNOWN
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI nanUNKNOWN
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion nanRECRUITING
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) nanRECRUITING
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging nanUNKNOWN
Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts nanCOMPLETED
Genetic Analysis of Fraser Syndrome and Fryns Syndrome nanCOMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients nanRECRUITING
Family Study of Head and Neck Cancers in Taiwan nanCOMPLETED
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NUP210 binder may also engage these)

ProteinNameSimilarity
Q9QY81 1.000 Q9QY81 →
P11654 1.000 P11654 →
Q684R7 0.952 Q684R7 →
O75051 0.949 O75051 →
Q9EQW8 0.943 Q9EQW8 →
O70472 0.942 O70472 →
Q6ZRP7 0.940 Q6ZRP7 →
Q9EQH7 0.939 Q9EQH7 →
P39038 0.939 P39038 →
Q6IEE7 0.939 Q6IEE7 →
P26013 0.938 P26013 →
Q8N475 0.938 Q8N475 →
Q6GQT9 0.938 Q6GQT9 →
Q5U4X8 0.938 Q5U4X8 →
Q1WIM1 0.938 Q1WIM1 →
Q6MZW2 0.938 Q6MZW2 →
Q8BFR2 0.937 Q8BFR2 →
Q6NW40 0.936 Q6NW40 →
B1AWJ5 0.936 B1AWJ5 →
Q5H8C1 0.936 Q5H8C1 →
P70207 0.935 P70207 →
Q9HCM2 0.935 Q9HCM2 →
ITGB8 Integrin beta-8 0.935 landscape →
Q9H3R1 0.935 Q9H3R1 →
Q80UG2 0.935 Q80UG2 →
Q3TMX7 0.935 Q3TMX7 →
P55283 0.935 P55283 →
Q812F8 0.935 Q812F8 →
J3S6Y1 0.934 J3S6Y1 →
Q8WU66 0.934 Q8WU66 →